Skip to main content

MDxHealth, NovioGendix Share $1.1M Grant for Bladder Cancer Research

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – MDxHealth today announced it will be sharing a $1.1 million grant with NovioGendix to develop tumor markers for bladder cancer.

The grant comes from Eurotrans-Bio, a European Commission initiative to foster cross-border R&D between companies and academia in the biotechnology space.

MDxHealth and NovioGendix together will use the funds to discover and validate tumor markers that may be predictive of tumor progression into the muscle in developing invasive-stage bladder cancer. The partners will use DNA methylation technologies, DNA sequencing, and RNA expression profiles on clinical samples collected from bladder cancer patients from the urology department at Radboud University Nijmegen Medical Centre in the Netherlands.

NovioGendix is a molecular diagnostics firm spun out of RUNMC.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.